These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 38428265)
21. Prognostic value of Tønnesen EMT; Stougaard M; Meldgaard P; Lade-Keller J J Clin Pathol; 2023 Dec; 77(1):54-60. PubMed ID: 36410939 [TBL] [Abstract][Full Text] [Related]
22. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. Shire NJ; Klein AB; Golozar A; Collins JM; Fraeman KH; Nordstrom BL; McEwen R; Hembrough T; Rizvi NA PLoS One; 2020; 15(9):e0238358. PubMed ID: 32881920 [TBL] [Abstract][Full Text] [Related]
23. Does Molecular Profiling of Karim NA; Ullah A; Pathrose P; Fathallah H; Perry A; Morris JC; Wang J; Starnes SL Curr Oncol; 2022 Jul; 29(7):4779-4790. PubMed ID: 35877239 [TBL] [Abstract][Full Text] [Related]
24. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related]
25. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC; Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642 [TBL] [Abstract][Full Text] [Related]
26. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862 [TBL] [Abstract][Full Text] [Related]
27. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses. Xu K; Lu W; Yu A; Wu H; He J BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512 [TBL] [Abstract][Full Text] [Related]
28. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. Provencio-Pulla M; Pérez-Parente D; Olson S; Hasan H; Balea BC; Rodríguez-Abreu D; Piqueras ML; Pal N; Wilkinson S; Vilas E; Ruiz-Gracia P; Cobo-Dols M Clin Transl Oncol; 2024 Jun; 26(6):1384-1394. PubMed ID: 38183584 [TBL] [Abstract][Full Text] [Related]
29. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. Liang Y; Maeda O; Kondo C; Nishida K; Ando Y PLoS One; 2024; 19(7):e0307580. PubMed ID: 39037971 [TBL] [Abstract][Full Text] [Related]
30. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679 [TBL] [Abstract][Full Text] [Related]
31. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008 [TBL] [Abstract][Full Text] [Related]
32. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855 [TBL] [Abstract][Full Text] [Related]
33. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821 [TBL] [Abstract][Full Text] [Related]
34. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related]
35. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022 [TBL] [Abstract][Full Text] [Related]
36. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357 [No Abstract] [Full Text] [Related]
37. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166 [TBL] [Abstract][Full Text] [Related]